Adventrx might submit chemotherapy drug to FDA this year

08/5/2009 | San Diego Business Journal

Adventrx Pharmaceuticals said it plans to submit its chemotherapy drug ANX-530 for FDA review before the end of the year after raising $1.36 million in a stock sale in June. The treatment is a reformulation of Navelbine, an intravenous chemotherapy drug used in nonsmall-cell lung cancer patients.

View Full Article in:

San Diego Business Journal

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC